Propel Bio Management, LLC Syndax Pharmaceuticals Inc Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q3 2024
A detailed history of Propel Bio Management, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Propel Bio Management, LLC holds 133,259 shares of SNDX stock, worth $2 Million. This represents 1.49% of its overall portfolio holdings.
Number of Shares
133,259
Previous 83,259
60.05%
Holding current value
$2 Million
Previous $1.71 Billion
50.07%
% of portfolio
1.49%
Previous 1.11%
Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
93.8MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$119 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$89.3 Million0.01% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$87.7 Million9.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$73.3 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.23MShares$63.6 Million0.01% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $849M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...